Cogent Biosciences, Inc.

This study tests an experimental drug called CGT9486 (bezuclastinib) in 140 people with advanced systemic mastocytosis, a rare and serious disease where too many mast cells build up in the body. The goal is to see if the drug can shrink or control the disease and how safe it is. …

This program provides an experimental drug, bezuclastinib, combined with sunitinib for people with advanced gastrointestinal stromal tumors (GIST) who have no other good treatment choices. It is for adults who have tried or cannot tolerate the standard drug imatinib. The combinat…

This program offers bezuclastinib, an investigational drug, to adults with systemic mastocytosis who have tried and failed other treatments or have no good options. The goal is to provide disease control for those with nonadvanced or advanced forms of the condition. Participants …

This early-stage study is testing an experimental drug called CGT4255 in about 100 adults whose advanced solid tumors have specific genetic changes (ERBB2 alterations or HER2 overexpression). The main goals are to check safety, find the best dose, and see if the drug shrinks tumo…